Have you or your loved ones been diagnosed with fallopian tube clear cell adenocarcinoma?

You may be eligible to participate in a fallopian tube clear cell adenocarcinoma clinical trial.

Have you or your loved ones been diagnosed with fallopian tube clear cell adenocarcinoma? You may be eligible to participate in a fallopian tube clear cell adenocarcinoma clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Fallopian Tube Clear Cell Adenocarcinoma Clinical Trial in Kearney NE
NCT02502266 | Phase 2 phase 3 | Interventional

Have you or your loved ones been diagnosed with fallopian tube clear cell adenocarcinoma?

You may be eligible to participate in a fallopian tube clear cell adenocarcinoma clinical trial.

Have you or your loved ones been diagnosed with fallopian tube clear cell adenocarcinoma? You may be eligible to participate in a fallopian tube clear cell adenocarcinoma clinical trial.

Active not recruiting

Female

18 Years +

This study is looking to recruit 562 Participants

This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned (recurrent) after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking enzymes needed for cell growth. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cediranib maleate and olaparib together may cause more damage to cancer cells when compared to either drug alone or standard chemotherapy.